In April 2026, the FDA removed a group of research peptides — including BPC-157, TB-500, MOTS-c, KPV, DSIP (Emideltide), Epitalon, and Semax — from Category 2 of its Section 503A review. Much of the online conversation read that step as the finish line: peptides were "coming back." As we covered in our reclassification breakdown, that reading was premature. Removal from Category 2 lifted an explicit prohibition designation, but it did not place any peptide on the authorized 503A bulk drug substances list. That decision runs through the Pharmacy Compounding Advisory Committee (PCAC).
The PCAC is scheduled to meet on July 23–24, 2026, and ahead of the meeting the FDA posted its scientific briefing materials for each of the seven first-batch peptides. According to industry trackers that reviewed the posted packages, the agency's briefing documents propose the same conclusion for all seven substances: do not add them to the 503A bulks list. Because those materials shape the questions put to the committee, they are the most consequential development in this process since the April action — and they point in a more restrictive direction than the spring headlines suggested.
Evidence and status note: the briefing-document contents summarized here are drawn from secondary reporting of FDA's posted materials, not from a peer-reviewed source. A PCAC recommendation is advisory. As of this writing, the FDA has not issued a final determination or rule on any of these peptides.
Which peptides, and what they were nominated for
The seven substances are split across the two meeting days, each evaluated in both free-base and acetate-salt forms:
- July 23 — BPC-157 (nominated around ulcerative colitis), KPV (wound healing and inflammatory conditions), TB-500 (wound healing), and MOTS-c (obesity and osteoporosis).
- July 24 — DSIP/Emideltide (opioid withdrawal, chronic insomnia, narcolepsy), Semax (cerebral ischemia, migraine, trigeminal neuralgia), and Epitalon (insomnia).
All seven already have dedicated evidence pages on this site. The nominated indications above are the specific use cases the committee is weighing — not endorsements, and in several cases narrower than the uses these peptides are discussed for in wellness circles.
The reasoning FDA reportedly cites
Across the seven briefing packages, the concerns fall into three familiar categories that the FDA applies to any substance considered for the 503A list:
1. The substances are not well-characterized
Reporting on the briefing materials describes the FDA flagging inconsistent naming conventions and missing substance-specific quality data — the kind of standardized characterization (identity, purity, impurity profile) the agency expects before a bulk drug substance can be compounded consistently and safely.
2. Little or no human efficacy data for the proposed route
For most of these peptides, the nominated route is injectable, and the FDA's materials reportedly found no adequate human clinical studies supporting effectiveness for the proposed uses. This is the recurring theme across our own evidence pages: much of the supporting data for BPC-157, TB-500, MOTS-c, and the others is preclinical (animal or in-vitro), classified C or D under our A–D system.
3. Insufficient human safety data, including immunogenicity
The briefing materials reportedly raise a specific concern about immunogenicity — the potential for peptide products to provoke an immune response, driven in part by aggregation. This has been one of the FDA's central objections to peptide compounding since the original Category 2 designation, and it remains unresolved by large-scale human data.
Advisory recommendation vs. final rule — why this is not the end
It is important to be precise about what the committee can and cannot do. The PCAC's role is advisory: it votes on recommendations, but it does not issue binding decisions. If the committee — or the FDA afterward — concludes that a substance is appropriate for the 503A list, the agency must then initiate a formal rulemaking process, including its own notice-and-comment period, which can take additional months.
In practical terms, three things follow. First, a briefing document that leans against listing makes a favorable committee vote less likely, but it does not preclude one. Second, even a favorable vote would not immediately make any of these peptides legally compoundable — rulemaking would still have to run its course. Third, the status quo persists in the meantime: licensed compounding pharmacies are not authorized to produce these seven peptides today, regardless of the April Category 2 removal.
What this means if you follow the peptide space
If you have been tracking the "peptides are back" narrative, the July briefing materials are a useful reality check. The regulatory door that appeared to open in the spring is, at the advisory stage, being held mostly closed pending stronger characterization and human data. That is consistent with the evidence picture we have maintained across these peptides all along: genuine mechanistic and preclinical interest, but a thin human clinical base.
None of this is medical or legal advice, and it is not a comment on whether any peptide "works." It is a status report on a specific regulatory process. Anyone making decisions based on compounding access should consult a qualified clinician and follow the actual FDA outcome rather than advance reporting. We will update this page after the July 23–24 votes and any subsequent FDA action.
Track the outcome
For the underlying evidence on each substance under review, see our pages on BPC-157, TB-500, MOTS-c, KPV, DSIP, Epitalon, and Semax. For the full regulatory timeline, see our 2026 peptide legality guide and reclassification breakdown.